Information Provided By: 
Fly News Breaks for June 26, 2019
ABBV, AGN
Jun 26, 2019 | 05:56 EDT
Mizuho analyst Irina Koffler downgraded Allergan (AGN) to Neutral from Buy and raised her price target on the stock to $188 from $171 after AbbVie (ABBV) announced a cash-and-stock deal to buy the company. She views the deal as "a hard-fought and timely exit" for shareholders, citing her concerns about the weakness in Allergan's aesthetics portfolio and the company's growth challenges.
News For AGN;ABBV From the Last 2 Days
There are no results for your query AGN;ABBV
